Medtronic PLC (NYSE:MDT) is set to report its fiscal fourth quarter 2026 results before the opening bell on Wednesday, June 3.

Analysts expect the Minneapolis, Minnesota-based company to post revenue of $9.61 billion, up 7.6% from the year-ago quarter, and EPS of $1.55, representing a 4.3% decline from the $1.62 reported for the same quarter last year.

Medtronic has entered into an agreement to buy SPR Therapeutics, a manufacturer of peripheral nerve stimulation devices to treat chronic pain, for $650 million in cash. The acquisition will mark Medtronic's third major purchase in 2026 and add to the company's neuromodulation business.

Medtronic shares rose 0.31% to close at $73.75 on Tuesday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look ...